To the Editor: COVID-19 being a multisystem inflammatory state, it is theoretically possible that any of the organ systems with the angiotensin-converting enzyme 2 (ACE2) receptors in abundance might be a source of some clinical manifestation. Endocrine and exocrine dysfunction of pancreas may be one such manifestation. Here, we present a series of 5 children (3 female and 2 male) with diabetes ketoacidosis (DKA) with COVID-19 admitted to our center between May 2020 and August 2020.
COVID antigen testing was positive for 4 children while RT-PCR report was positive for 1 child. In the present case series, 4 children had severe DKA while 1 had moderate DKA; acute kidney injury was present in all children but only one patient required renal replacement therapy while others improved with medical management during treatment course. Cerebral edema was present in 3 patients and it was managed conservatively. None of them had any significant radiograph findings and did not require any supplemental oxygen support.
Lymphopenia was present in 1 patient (severe DKA), Serum ferritin was done in 2 patients and it was within normal limit, D-dimer was done in 3 patients and it was elevated in all 3 of them (severe DKA), C-reactive protein and procalcitonin was positive in one patient (severe DKA).
COVID-19 and DKA are both hyperinflammatory states, which, in conjunction, would theoretically result in hyperacute rapidly progressive illness [1]. The exact mechanism of such presentation in association with SARS CoV2 is still presumptive. ACE2 is highly expressed in the lungs and pancreas and entry of SARS-CoV-2 into pancreatic islet cells may directly aggravate beta cell injury [2, 3] and massive cytokine release can damage islet cells [4].
Though the exact causal and co-existence relationship between diabetic ketoacidosis and COVID-19 is still presumptive, it is wise to be watchful of its occurrence. This may serve as an opportunity to institute-appropriate COVID-19 screening measures in children presenting as DKA.
References
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–10.
Roca-Ho H, Riera M, Palau V, et al. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci. 2017;18:E563.
Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41(2):127–33.
Palermo NE, Sadhu AR, McDonnell ME. Diabetic ketoacidosis in COVID-19: unique concerns and considerations. J Clin Endocrinol Metab. 2020;105(8):1–11.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
K, Y., A. V, L., Pujari, C.G. et al. COVID with Diabetic Ketoacidosis: Intriguer or Consequence. Indian J Pediatr 88, 599 (2021). https://doi.org/10.1007/s12098-021-03678-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-021-03678-9